Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company's partner, Vical Incorporated, presented positive interim safety and tolerability data on 18 subjects from an ongoing Phase I clinical trial using Inovio's electroporation technology for intratumoral delivery into melanoma tumors of plasmid DNA (pDNA) encoding interleukin-2 (IL-2). The treatment demonstrated objective tumor responses in treated and untreated lesions. The data were presented at the annual meeting of the American Society of Clinical Oncology (Chicago, June 1-5) by Jon M. Richards, M.D., Ph.D., Lutheran General Hospital Division of Hematology/Oncology. Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

The systemic delivery of high-dose recombinant IL-2 to treat melanoma is limited by significant toxicity. An alternative method for extended dosing of IL-2 that may reduce toxicity is by intratumoral injection (followed by electroporation to facilitate cellular uptake) of a plasmid DNA designed to produce IL-2 in the body. The primary objective of this ongoing Phase I pDNA IL-2/electroporation study is to evaluate the safety and tolerability of the latter approach in stage three and four metastatic melanoma patients. In the first stage of the trial, four treatment groups received escalating doses of 0.5, 1.5, 5 (mg per tumor), and 15 mg (5 mg in each of 3 tumors). In the ongoing second stage, patients are treated with the 15 mg dose.

The interim study results show that no serious adverse events related to the study drug or administration procedure have been reported and the treatment was well tolerated. The majority of related adverse events
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... ,culotte, technique better?, CHICAGO, March 29 When ... of two coronary arteries -- or a,bifurcation lesion -- ... vessels without blocking the opening to the side branch. ... on which of,two techniques produces the best long-term results ...
Cached Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... cent of Canadians surveyed said they would participate in ... number of genetic conditions, only 80 per cent said ... would sequence their newborns, genomes.,Most newborns in North America ... or two of life in which a tiny amount ... for about five to 54 conditions, depending on the ...
(Date:4/17/2014)... more research to be carried out into HIV ... In a paper in The Lancet Infectious ... colleagues in the department of Parasitology and researchers ... University of Cambridge and the Royal Veterinary College ... of HIV/AIDS and schistosomiasis of children, and found ...
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team that ... of Texas Health Science Center at San Antonio, Johns Hopkins ... protein that helps a common fungus to infect the body. ... infections, diaper rashes and oral thrush, and is the most ...
(Date:4/15/2014)... Handling frozen fish caused nearly half of all injuries ... injuries on freezer-longliner vessels operating off the coast of ... Many of those injuries and others aboard the two ... interventions, and the research methods used in the study ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... PARSIPPANY, N.J., July 14 alli spokeswoman Wynonna Judd ... of Fame in Nashville to celebrate her progress since starting the ... having more energy and feeling better. The concert was held exclusively ... commitment to live healthier lives. , , ...
... , , , , ... smoked her first cigarette. Now that she is 45, she still smokes despite ... start smoking if they have a parent who smokes - and in Crawford,s ... met and married her husband - also a smoker - in Roanoke. The ...
... , RESTON, Va., July ... products, announced today that Johns Hopkins Medical Institutions has ... software solution. Perceptrak will assist corporate security personnel in ... campus. , , "Perceptrak ...
... , , ... Nutritionals, Inc. ("Atkins(TM)"), with its market-leading, weight-management shakes and snack bars, has ... Penne Pasta that has half the carbs of regular pasta. Both products ... to reduce the refined carbohydrates and sugars in their diets. Starting ...
... , SAN DIEGO, July 14 ... inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 ... but also its newly approved competitor, Effient. In obtaining a ... to determine the response of an individual patient to their ...
... July 14 (HealthDay News) -- Jogging can be great for ... running can be tough on the body. All that pounding ... ankle sprains, plantar fasciitis (heel pain), knee problems and issues ... sure you take precautions, including wearing the right shoes, taking ...
Cached Medicine News:Health News:Wynonna Judd Celebrates Her Progress on alli With Private Concert at Legendary Venue 2Health News:Wynonna Judd Celebrates Her Progress on alli With Private Concert at Legendary Venue 3Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 2Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 3Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 4Health News:Johns Hopkins Medical Institutions Deploys Perceptrak(R) by Cernium 2Health News:Bread, Pancakes and Pasta on Atkins? Yes, That's Right! 2Health News:Bread, Pancakes and Pasta on Atkins? Yes, That's Right! 3Health News:Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R)) 2Health News:Get the Most Out of Your Run 2Health News:Get the Most Out of Your Run 3
... , , The Shortyavailable with both Impact ... our face-to-face relationship with the scientific community generates ... pipetting easier and more effective., Shorter and ... Gets you closer to the working area ...
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Medicine Products: